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ABSTRACT

Service perspective of three step-up strategies
for patients with asthma uncontrolled by

Introduction: Data from different healthcare
systems on relative cost-effectiveness of

inhaled corticosteroid (ICS) monotherapy.
Methods: This was a historical matched cohort

asthma step-up therapy strategies are required
to inform decision-makers and clinicians. Our

cost-effectiveness analysis of anonymized
medical records for patients with asthma of

objective was to compare cost-effectiveness

age

from the United Kingdom National Health

comparisons of step-up therapy using
increased dose (C50%) of extrafine-particle ICS
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12–80 years.

We

conducted

two-way

or add-on long-acting b2-agonist (LABA) via
fixed-dose combination (FDC) ICS/LABA
inhaler

or

via

separate

inhaler.

The

incremental cost-effectiveness ratio (ICER) was
calculated using asthma-related direct costs
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during one outcome year and a composite

developing guidelines in settings with strong

measure of risk-domain asthma control (no
asthma-related hospital attendance, acute oral

economic constraints.
Trial Registration: ClinicalTrials.gov identifier:

corticosteroids, or consultation
respiratory tract infection).

NCT01697722.
Funding: Teva Pharmaceuticals Limited, Petach

for

lower

Results: Patients prescribed ICS dose step-up

Tikva, Israel.

(n = 3036)
had
baseline-adjusted,

Keywords: Asthma;

significantly
lower
mean
asthma-related

Beclomethasone

healthcare costs during the outcome year than
those prescribed FDC ICS/LABA (n = 3036;

dipropionate hydrofluoroalkane; Budesonide/
formoterol
fumarate
dehydrate;
Cost-

mean difference, £124/year). ICS dose step-up

effectiveness;

had 56% probability of being less costly and
marginally less effective (a trade-off), with ICER

corticosteroid;
Fixed-dose
combination;
Fluticasone propionate/salmeterol xinafoate;

of £51,449 per additional patient controlled
with FDC; and ICS dose step-up had 44%

Long-acting b2-agonist

Extrafine-particle

inhaled

probability of being the preferred treatment
strategy (less costly and more effective). In a
second comparison, ICS step-up (n = 3232) had

INTRODUCTION

100% probability of being cheaper and more
effective than adding LABA to ICS via separate

An estimated 334 million people worldwide
have asthma, including 5.4 million people in

inhalers (n = 6464).
Conclusion: For asthma

the United Kingdom (UK) on current asthma

increasing ICS dose using extrafine-particle ICS

therapy [1, 2]. Asthma is an important cause of
healthcare
resource
utilization
and

is significantly less costly from the payer
perspective and marginally (non-significantly)

health-related quality of life impairment [3].
The treatment of asthma is expensive, costing

less effective than FDC ICS/LABA therapy
containing standard fine-particle ICS. These

the UK National Health Service (NHS) an

step-up

therapy,

findings apply primarily to the UK healthcare
system

but

warrant

consideration

when

estimated £1 billion per year in direct costs,
mostly attributable to the cost of prescription
medications and hospital admissions [2, 4].
Healthcare resource use and the direct costs of
asthma are highest for patients with suboptimal
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asthma control [5–7]. Considering these costs, it
is of utmost importance to generate real-life
cost-effectiveness data to help decision-makers
and clinicians in their decisions regarding the
choice between available treatment options.
The goal of asthma therapy is to achieve the
two facets of asthma control, namely, current
symptomatic control and minimized risk of
future acute exacerbations, which can be life
threatening [3]. Asthma therapy is prescribed
using a stepwise approach, beginning with
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(reliever

exacerbation rates may be more appropriate for

medication, such as short-acting b2-agonist

making treatment decisions [16, 17]. In addition,

[SABA]) at step 1 and progressing, as needed,
to controller or maintenance therapy at step 2

most economic models relied on RCTs in which
standard fine-particle ICS were administered,

with an anti-inflammatory medication, such as
an inhaled corticosteroid (ICS). For patients

namely, ICS with particles of median mass
aerodynamic diameter (MMAD) of[2–5 lm.

receiving ICS monotherapy whose asthma

Instead,

remains uncontrolled, asthma management
guidelines then recommend at step 3 the

(MMAD, *1 lm) may better treat the small
airways, where inflammation is often present in

addition of a long-acting bronchodilator (e.g.,
long-acting b2-agonist [LABA]), with secondary

asthma, and thus may be more effective than
fine-particle ICS, at least for patients with small

(less-preferred) options of increasing the ICS

airway involvement [18, 19].

dose or adding a leukotriene
antagonist (LTRA) [3, 8].

receptor

In a prior historical matched cohort study
comparing step-up alternatives for patients with

These recommendations are based on the
results of randomized controlled trials (RCTs)

asthma treated in community settings [20], we
found that increasing the ICS dose was as

[3, 8]; however, RCT results have limited

effective in controlling exacerbations over the

generalizability to actual clinical practice. By
one estimate up to 95% of patients with asthma

subsequent year as adding a LABA by fixed-dose
combination (FDC) ICS/LABA inhaler. The

would not be eligible for RCTs because of
restrictive RCT eligibility criteria, such as the

objective of the present historical matched
cohort cost-effectiveness analysis was to

exclusion of smokers or obese patients [9].
Moreover, adherence to therapy and inhaler

compare direct asthma-related healthcare costs
and cost-effectiveness from the UK NHS

device technique are better in RCTs than among

perspective of three common step-up options

patients in clinical practice [10, 11]. Relevantly
for the step-up comparisons between increasing

for asthma: increased dose of extrafine-particle
ICS, add-on LABA by FDC ICS/LABA inhaler,

ICS dose and add-on LABA, most RCTs require
enrolled patients to demonstrate substantial

and add-on LABA by separate inhaler. Our
hypothesis was that increasing the dose of an

reversibility of airflow obstruction to a SABA,

extrafine-particle ICS would be a cost-effective

thereby
selecting
for
bronchodilator
responsiveness and excluding the estimated

alternative to therapy with ICS plus LABA in
combination or separate inhalers for adults with

70% of patients with asthma who fail to
demonstrate
sufficient
bronchodilator

evidence of persistent asthma. Additionally, we
hypothesized that FDC ICS/LABA inhalers

reversibility at any given point in time [9].

would be more cost-effective than separate

Cost-effectiveness
analyses
of
asthma
therapies are usually based on economic

ICS/LABA inhalers.

models drawing on data from
12–16 weeks’ duration [12–15].

METHODS

short-acting

bronchodilator

RCTs of
However,

the

newer

extrafine-particle

ICS

long-term clinical practice data may be more

Data Sources and Patients

directly relevant to inform economic decisions
regarding treatment choices for asthma, and

The anonymized patient data for this matched

effectiveness

cohort study were drawn from two UK primary

parameters

such

as

annual
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care electronic datasets used extensively for

Tikva, Israel), by pressurized metered-dose

pharmacoepidemiologic research and described

inhaler (pMDI) or breath-actuated pMDI
(BAI)

in detail in prior publications: the General
Practice Research Database (GPRD), now part of

(2)

the Clinical Practice Research Datalink, and the
Optimum Patient Care Research Database

LABA combination of either fluticasone
propionate/salmeterol
xinafoate
Ò
(Seretide , GlaxoSmithKline, Middlesex,

(OPCRD) [21–24]. Approval was given for use of
the GPRD data by the GPRD Independent
Scientific Advisory Committee. The OPCRD has

UK), or budesonide/formoterol fumarate
dihydrate
(SymbicortÒ,
AstraZeneca,

been approved by Trent Multi Centre Research
Ethics Committee for clinical research use, and
the study protocol was approved by ADEPT
(Anonymised Data Ethics Protocols and
Transparency Committee), OPC’s independent
scientific advisory committee. Informed patient
consent was neither required nor possible to

FDC ICS/LABA: addition of LABA (with no
change in ICS dose) using a fixed-dose ICS/

London, UK); or
(3)

Separate ICS ? LABA: addition of LABA by
separate pMDI or BAI, with no change in
ICS drug, dose, or inhaler.

Resource Use and Costs

obtain for this non-interventional study using
anonymized data. The study was conducted
according to standards recommended for
observational research (further details in the
supplementary material) [25].
The study period ran from January 1997
through January 2011. We included patients
with asthma and no other chronic respiratory
disease who were 12–80 years old. We excluded
active smokers who were 61–80 years old because
undiagnosed or comorbid chronic obstructive
pulmonary disease is more likely in this older age

Information on asthma-related resource use was
extracted from the databases. We calculated
total asthma-related direct costs in 2011 sterling
(£) from the UK NHS perspective using unit
costs obtained from UK national data sources
[26–28],
Table S1,

summarized
in
supplementary
with further details in the

supplemental

Methods

section

in

the

supplementary material.
Effectiveness Measure

group than in younger patients [3, 8]. Additional
inclusion criteria were ICS monotherapy for
asthma during one baseline year; a step up in

We used a composite database measure for
risk-domain
asthma
control
as
the

asthma therapy as one of the three options
described below; and 2 years of continuous

effectiveness measure, as reported in previous

records in the GPRD or the OPCRD, including

publications [20, 29–31], defining asthma
control as including all of the following: (1)

one baseline year before and one outcome year
after the step-up date (defined as the index date).

no asthma-related hospital attendance or
admission,
emergency
department
(ED)

The three step-up options were as follows:
(1) Extrafine ICS step-up: an increase in ICS

attendance,

dose of C50% as an extrafine-particle ICS
(beclomethasone
dipropionate
Ò

hydrofluoroalkane [HFA]; Qvar , Teva
Pharmaceutical Industries Ltd., Petach

out-of-hours

attendance,

or

outpatient hospital attendance; and (2) no
prescription for an acute course of oral
corticosteroids [32]; and (3) no primary care
consultation for lower respiratory tract
infection [33, 34].

Pulm Ther

Statistical Analyses

during the outcome year, both unadjusted and
adjusted for potential confounders. Adjusted

We conducted matched cohort analyses, using
two-way matching for the three cohorts, to
compare outcomes for age- and sex-matched
patients with similar asthma severity and
baseline asthma control. Patients were
matched sequentially on sex, age, the last ICS
daily dose prescribed before the index date,
asthma control status, mean daily dose of SABA,
and the number of primary care consultations
for asthma with no oral corticosteroid
prescription (details in the supplementary
material). Effectiveness and asthma-related
costs were compared by two-way comparisons
between (1) the ICS step-up cohort versus the
FDC ICS/LABA cohort (comparison 1); (2) the
ICS

step-up

cohort

versus

the

separate

ICS ? LABA cohort (comparison 2); and (3) the
separate ICS ? LABA cohort versus the FDC ICS/
LABA cohort (comparison 3).
The costs of treatments were compared via
the

differences

in

mean

asthma-related

healthcare costs per patient per year during
the outcome period, both unadjusted and
adjusted for potential confounders (Table S2 in
the
supplementary
material).
Two-way
comparisons

of

summary

costs

between

matched cohorts were carried out using
conditional logistic regression. Generalized
linear models with a log link and gamma
distribution were used to estimate adjusted

proportions were estimated using generalized
linear models with a logit link and binomial
distribution. Proportions and differences in
proportions of patients with asthma control
were

reported

with

95% CIs

found

by

bootstrapping methods, using the 1000
random samples taken, with replacement,
from the dataset.
The
two-way
asthma-related

differences

costs

and

in

total

proportions

of

patients with asthma control for the 1000
random samples were displayed graphically on
cost-effectiveness planes. When the point
estimates for differences in costs and
effectiveness indicated a trade-off between
treatments (Fig. 1, quadrants I and III), we
calculated an incremental cost-effectiveness
ratio (ICER) as the ratio of the difference in
total asthma-related healthcare costs per patient
per year (namely, the incremental cost) to the
difference in proportions of patients with
asthma control (namely, the incremental gain
in effectiveness). When all the replicated data
were in one quadrant of the cost-effectiveness
plane, the ICER was reported with a 95% CI
found by bootstrapping methods. When
replicated

data

covered

more

than

one

quadrant, we produced a cost-effectiveness
acceptability curve (CEAC) in conjunction
with the ICER [36–38].

mean asthma-related healthcare costs per year
during the outcome period. Differences in
adjusted mean costs are reported with 95%

RESULTS

confidence
intervals
(CIs)
found
by
bootstrapping methods, using 1000 random

Patients

samples taken, with replacement, from the

We identified 5492, 9207, and 20,657 eligible
patients who were prescribed extrafine-particle

dataset [35].
The effectiveness of treatments for matched
cohorts was compared via the difference in the
proportion of patients with asthma control

ICS dose step-up, add-on LABA by FDC ICS/
LABA inhaler, and add-on LABA to ICS by
separate

LABA

inhaler,

respectively.

The

Pulm Ther

Fig. 1 Cost-effectiveness planes showing the spread of the
estimated differences in cost and effectiveness, based on
1000 replicated samples, between a the ICS step-up cohort
and the FDC ICS/LABA cohort and b the ICS step-up
cohort and the separate ICS ? LABA cohort. Depending
where the data points lie, the four quadrants of the
cost-effectiveness plane would depict the results of a step-up
in asthma therapy by increased dose of extraﬁne-particle
ICS, relative to add-on LABA with ICS in combination

(a) or separate (b) inhalers, as follows: Quadrant I: ICS
step-up more costly and more effective (a trade-off);
Quadrant II: ICS step-up more costly and less effective
(thus, FDC ICS/LABA or separate ICS ? LABA dominant); Quadrant III: ICS step-up less costly and less
effective (a trade-off); and Quadrant IV: ICS step-up less
costly and more effective (ICS step-up dominant). FDC
ﬁxed-dose combination, ICS inhaled corticosteroid, LABA
long-acting beta2-agonist

Pulm Ther

matching for the ICS step-up cohort versus the

the ICS step-up cohort were significantly lower

separate ICS ? LABA cohort and for the FDC

than those for patients in the FDC ICS/LABA

ICS/LABA
cohort
versus
the
separate
ICS ? LABA cohort was in 1:2 ratios because of

cohort (mean, £203 vs. £327; Table 2). When
adjusted mean costs were combined with the

a baseline imbalance in numbers of unmatched
patients. Baseline characteristics of matched

adjusted effectiveness results—using asthma
control as the effectiveness measure—there

patients in comparisons 1 and 2 are in

was a 56% probability that stepping up to a

Table S3 in the supplementary material.
Approximately 22% of patients in comparisons

higher dose of extrafine-particle ICS would be
less costly but less effective (a trade-off) and a

1 and 2 were smokers, and approximately 18%
were ex-smokers (Table S3).

44% probability that ICS step-up would be the
preferred treatment strategy (less costly and

Full results for comparison 3 (FDC ICS/LABA

more effective). The uncertainty around the

versus separate ICS ? LABA) are reported in
Tables S4–S6 in the supplementary material.

point
estimates
is
illustrated
in
the
cost-effectiveness plane (Fig. 1a). The point

In all matched cohorts uncontrolled asthma
was associated with increased costs (Table S7).

estimate for the ICER was £51,449. The CEAC
showed that for no additional cost (willingness
to

Comparison 1: Asthma Step-Up Therapy

pay = £0)

an

increased

dose

of

the

Using an Increased Dose

extrafine-particle ICS was the cost-effective
option, since a zero value for the willingness

of Extrafine-Particle ICS Versus Add-On
LABA by FDC ICS/LABA Inhaler

to pay implies that only the cost is important in
the cost-effectiveness calculation (Fig. 2).

After matching, there were 3036 patients in the

Comparison 2: Asthma Step-Up Therapy

ICS step-up and the FDC ICS/LABA cohorts.
Patients’ mean (standard deviation) age was 43

Using an Increased Dose

(16) years, 60% being women (Table S3 in the

of Extrafine-Particle ICS Versus Add-On
LABA by Separate Inhaler

supplementary material).
The percentage of patients meeting the

After matching, there were 3232 patients in the

risk-domain asthma control measure increased
from 65% at baseline to 75% in both cohorts

ICS step-up cohort and 6464 patients in the
separate ICS ? LABA cohort. Baseline patient

during

complete

characteristics and asthma-related resource use

effectiveness results for comparison 1 have
been previously published [20].

were similar to those of comparison 1 (Table S3
in the supplementary material).

During the outcome year, asthma-related
resource use was similar in the two cohorts

The percentage of patients meeting the
risk-domain asthma control measure increased

with the exception of expected differences

from 65% at baseline to 75% in the ICS step-up

related to study design, such as use of ICS and
FDC ICS/LABA inhalers and a greater number of

cohort and to 71% in the separate ICS ? LABA
cohort at outcome.

SABA inhalers used by the ICS step-up cohort
(Table 1).
The
mean
baseline-adjusted,

During the outcome year, most categories of
asthma-related resource use and costs were

asthma-related healthcare costs for patients in

significantly lower for the ICS step-up cohort

the

outcome

year.

The

Pulm Ther

Table 1 Mean asthma-related drug prescriptions and unadjusted costs during the outcome year for patients receiving a
step-up in ICS dose versus add-on LABA by FDC ICS/LABA inhaler (comparison 1)
Asthma-related resourceb

Mean (SD) resource use

Mean (SD) resource cost, £
ICS dose
step-up
(N 5 3036)

FDC ICS/
LABA
(N 5 3036)

P valuea

\0.001

92 (68)

8 (24)

\0.001

8.8 (7.3)

\0.001

34 (135)

245 (198)

\0.001

0.8 (22.4)

0.2 (4.6)

\0.001

11 (51)

3 (29)

\0.001

Short-acting b2-agonist inhalers

7.1 (7.7)

5.4 (7.1)

\0.001

27 (58)

22 (55)

\0.001

Leukotriene receptor antagonist
prescriptions

0.2 (1.1)

0.2 (1.2)

0.11

6 (41)

7 (40)

0.28

Antibiotic prescriptionsc

1.0 (1.6)

1.0 (1.5)

0.39

3 (11)

4 (15)

0.30

Oral corticosteroid prescriptions

0.3 (1.0)

0.3 (0.9)

0.067

1 (7)

1 (5)

0.67

Total mean medication costs

–

–

–

174 (182)

290 (220)

\0.001

Total mean medication costs,
excluding ICS

–

–

–

49 (92)

37 (77)

\0.001

Primary care asthma
consultations

0.9 (1.3)

0.9 (1.3)

0.12

32 (47)

34 (46)

0.12

Total asthma-related
hospitalizations

0.0 (0.3)

0.1 (0.3)

0.21

9 (67)

10 (68)

0.34

Asthma-related inpatient

0.0 (0.1)

0.0 (0.1)

0.72

3 (54)

4 (54)

0.72

Asthma-related outpatient

0.0 (0.2)

0.0 (0.3)

0.25

5 (34)

6 (36)

0.25

Asthma-related emergency
department visit

0.0 (0.1)

0.0 (0.1)

0.64

0.7 (11)

0.9 (12)

0.64

ICS dose
step-up
(N 5 3036)

FDC ICS/
LABA
(N 5 3036)

P value

ICS inhalers

5.7 (4.1)

0.8 (2.3)

FDC ICS-LABA inhalers

0.9 (3.2)

Long-acting b2-agonist inhalers

a

Total asthma-related primary and –
secondary care, including ICS
costs

–

–

215 (226)

334 (254)

\0.001

Total asthma-related primary and –
secondary care, excluding ICS
costs

–

–

90 (139)

81 (123)

\0.001

Mean values are reported, despite substantially skewed distributions, because mean values can be multiplied by a target
population to estimate total costs and thus are of most interest for policy makers and providers
FDC Fixed-dose combination, ICS Inhaled corticosteroid, LABA Long-acting b2-agonist, SD Standard deviation
a
Conditional logistic regression
b
Asthma-related includes all database events coded for asthma and lower respiratory tract infection
c
Antibiotics prescribed with accompanying lower respiratory tract infection Read code
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Table 2 Incremental cost-effectiveness analysis: ICS step-up versus FDC ICS/LABA inhaler (comparison 1) and ICS
step-up versus ICS ? LABA in separate inhalers (comparison 2)
Comparison 1

Comparison 2

ICS dose
step-up
(N 5 3036)

FDC ICS/
LABA
(N 5 3036)

ICS dose
step-up
(N 5 3232)

Separate
ICS 1 LABA
(N 5 6464)

Risk-domain asthma control, adjusted
OR (95% CI)

0.99 (0.88–1.12)a

1.00

1.25 (1.13–1.38)d

1.00

Risk-domain asthma control, adjusted
proportion (95% CI)b

0.44 (0.37–0.50)a

0.44
(0.37–0.51)a

0.61 (0.59–0.63)d

0.56
(0.53–0.58)d

Difference relative to add-on LABA
(95% CI)b

0.002 (-0.033 to
0.026)

Adjusted mean asthma-related
healthcare costs per patient per year
(95% CI)b,c

£203 (£197–£210)

Difference relative to add-on LABA
(95% CI)b

-£124 (-£135 to
-£114)

0.06 (0.03–0.08)
£327
(£319–£336)

£204 (£197–£210)

£337
(£332–£344)

-£134 (-£142 to
-£125)

Trade-off: ICS step-up signiﬁcantly less ICS step-up dominant: less costly and
costly but marginally less effective
more effective than separate
ICS ? LABA
Cost-effectiveness ratio (ICER)

£51,499

Conﬁdence intervals determined using bootstrapping methods with 1000 random samples
CI conﬁdence interval, FDC ﬁxed-dose combination, ICER incremental cost-effectiveness ratio, ICS Inhaled corticosteroid,
LABA long-acting b2-agonist, OR Odds ratio
a
Adjusted for: smoking status (current smoker/ex-smoker/nonsmoker/not speciﬁed), outpatient department attendance
for asthma/lower respiratory reasons, number of acute oral corticosteroid prescriptions, and oral thrush
b
Conﬁdence intervals determined using bootstrapping methods with 1000 random samples
c
Adjusted for baseline asthma-related healthcare costs
d
Adjusted for number of acute oral corticosteroid prescriptions
(Table 3), and the mean baseline-adjusted,
asthma-related healthcare costs for patients in

DISCUSSION

the ICS step-up cohort were significantly lower
compared with those for patients remaining on

In this matched cohort cost-effectiveness study,
UK patients stepping up to a higher dose of

the same ICS dose but adding a separate LABA

extrafine-particle ICS had significantly lower
baseline-adjusted
mean
asthma-related

(£204 vs. £337; Table 2). When costs were
combined with the adjusted effectiveness

healthcare

costs

compared

with

patients

results, there was a 100% probability that
stepping
up
to
a
higher
dose
of

stepping up to an FDC ICS/LABA inhaler
(mean difference of £124 per annum) during

extrafine-particle ICS would be less costly and

one outcome year. When these costs were
combined with the adjusted effectiveness

more effective than adding a LABA by separate
inhaler (Fig. 1b).

results, there was a 56% probability that

Pulm Ther

Fig. 2 Cost-effectiveness acceptability curve for an
increased dose of extraﬁne-particle ICS (ICS step-up)
relative to add-on LABA in a ﬁxed-dose combination
inhaler with ICS (ICS/LABA combination): Probability of

ICS step-up being cost-effective from the UK NHS
perspective, adjusted results. ICS Inhaled corticosteroid,
LABA Long-acting beta2-agonist, UK NHS United Kingdom National Health Service

stepping up to a higher dose ICS would be less
costly but less effective (a trade-off); a point

supplementary material) prescribing an FDC
ICS/LABA inhaler was more costly but also

estimate for the ICER, the monetary value of the

more effective (with 100% probability) than

intangible benefit to patients or society beyond
the cost to achieve an additional controlled

prescribing a separate add-on LABA inhaler.
This study compared asthma-related direct

patient using an FDC ICS/LABA inhaler, was
£51,449, reflecting the significantly higher costs

costs for different step-up strategies in a primary
care setting, which is where most patients with

of

non-significant

asthma receive treatment in the UK, as in many

difference in effectiveness between treatments.
There was a 44% probability that stepping up to

countries [39, 40]. There are only a few studies
that have examined real-life comparative costs

a higher dose of extrafine-particle ICS would be
the preferred treatment strategy (less costly and

for asthma step-up therapy [41, 42]. For patients
with recent exacerbation or frequent SABA use

more effective). In our second comparison, ICS

identified in a recent retrospective cohort study

step-up was the preferred treatment strategy
compared with adding LABA via separate

conducted using a large US health insurance
dataset, Hagiwara and coworkers [41] found

inhaler: there was a 100% probability that
stepping
up
to
a
higher
dose
of

that fluticasone/salmeterol combination was
more effective in decreasing exacerbations and

extrafine-particle ICS would be less costly and

SABA use but more expensive than ICS dose

more effective. Of the two add-on LABA
alternatives (comparison 3, reported in the

step-up with fluticasone. In a broad United
States (US) asthma population studied in

FDC

therapy

and

the
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Table 3 Mean asthma-related drug prescriptions and unadjusted costs during the outcome year for patients receiving a
step-up in ICS dose versus add-on LABA by separate inhaler ? ICS (comparison 2)
Asthma-related resourcec

Mean (SD) resource use

Mean (SD) resource cost, £
a

P valuea

ICS dose
step-up
(N 5 3232)

Separate
ICS 1 LABA
(N 5 6464)

P value

ICS inhalers

5.7 (4.1)

4.5 (4.1)

\0.001

91 (69)

43 (50)

\0.001

Fixed-dose combination ICS/
LABA inhalers

0.9 (3.2)

1.6 (4.5)

\0.001

34 (134)

57 (168)

\0.001

Long-acting b2-agonist inhalers

0.8 (21.8)

5.8 (24.7)

\0.001

11 (52)

155 (150)

\0.001

Short-acting b2-agonist inhalers 7.1 (8.0)

6.5 (7.7)

\0.001

27 (58)

25 (51)

0.072

Leukotriene receptor antagonist 0.2 (1.0)
prescriptions

0.2 (1.2)

0.26

6 (42)

6 (40)

0.85

Antibiotic prescriptions

1.0 (1.7)

1.0 (1.9)

0.54

3 (11)

4 (15)

0.33

Oral corticosteroid prescriptions 0.4 (1.0)

0.4 (1.1)

\0.001

1 (6)

2 (6)

\0.001

ICS dose
step-up
(N 5 3232)

Separate
ICS 1 LABA
(N 5 6464)

Total mean medication costs

–

–

–

174 (182)

292 (242)

\0.001

Total mean medication costs,
excluding ICS

–

–

–

49 (92)

192 (173)

\0.001

Primary care asthma
consultations

0.9 (1.3)

1.1 (1.4)

\0.001

33 (48)

41 (52)

\0.001

Total asthma-related
hospitalizations

0.0 (0.3)

0.1 (0.3)

0.050

8 (62)

13 (93)

0.006

Asthma-related inpatient

0.0 (0.1)

0.0 (0.1)

0.011

3 (49)

7 (80)

0.011

Asthma-related outpatient

0.0 (0.2)

0.0 (0.3)

0.16

4 (32)

5 (36)

0.16

Asthma-related emergency
department visit

0.0 (0.1)

0.0 (0.1)

0.94

1 (13)

1 (13)

0.94

Total asthma-related primary –
and secondary care, including
ICS costs

–

–

215 (224)

345 (283)

\0.001

Total asthma-related primary –
and secondary care, excluding
ICS costs

–

–

90 (136)

246 (209)

\0.001

Mean values are reported, despite substantially skewed distributions, because mean values can be multiplied by a target
population to estimate total costs and thus are of most interest for policy makers and providers
ICS inhaled corticosteroid, LABA long-acting b2-agonist, SD standard deviation
a
Conditional logistic regression
b
Asthma-related includes all database events coded for asthma and lower respiratory tract infection
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and

our definition of asthma control, as 58–65% of

asthma-related healthcare resource utilization

each cohort were evaluated as controlled at

were lower with ICS monotherapy as compared
with FDC ICS/LABA therapy (cost-effectiveness

baseline
according
to
our
measure.
Nevertheless, all patients were prescribed a

was not reported) [42]. Other published
cost-effectiveness analyses based on short-term

step-up in therapy at the index date, which
suggests that they or their physician did not

RCT results report that FDC ICS/LABA therapy,

consider their asthma to be well-controlled.

while
more
expensive,
usually
meets
benchmarks for cost-effectiveness [12–15].

We had no way to measure patient
satisfaction with therapy; however, we inferred

Administering LABA by separate inhaler was
not a cost-effective alternative in this study as

from the treatment change data in the
companion effectiveness study that there were

compared with either ICS step-up or an FDC

no major differences in patient satisfaction

ICS/LABA inhaler. Similar findings were
reported in prior RCTs [13]. In addition,

between ICS step-up and FDC ICS/LABA
step-up as the same proportions of patients in

administering LABA by separate inhaler is
discouraged by asthma guidelines because

the two cohorts changed therapy during the
outcome year [20]. Nevertheless, the issue of

LABA monotherapy (without ICS) has been

patient satisfaction with step-up therapy would

associated with serious adverse asthma-related
outcomes, including deaths, seen in early trials

be an important outcome to explore in a
pragmatic trial. Patient satisfaction and patient

[8, 43]. Instead, an FDC ICS/LABA inhaler is
recommended to ensure that patients take

preferences are potentially important influences
on patient adherence to therapy and hence

concomitant ICS.
A strength of this study is the large patient

must be factored into clinical prescribing
decisions [3, 8]. In addition, ICS doses should

population, with over 38,000 patients studied,

be tailored to the level of symptom control,

and the minimal exclusion criteria designed to
capture data for a broad general population

lung function, and exacerbations, all relating to
the degree of airways inflammation.

treated for asthma in primary care. Treatment
cohorts were matched according to several

Double counting may have occurred in this
analysis because the numerator included the

criteria reflecting baseline asthma severity and

difference in costs of asthma-related resource

control. Effectiveness measures were adjusted
for residual confounding. Nonetheless, we

utilization and the asthma control effectiveness
measure was a function of asthma-related

cannot exclude the possibility of unrecognized
confounders, including measures that were not

events. Therefore, the cost estimates in the
ICERs are interpreted as the willingness-to-pay

available for all patients, such as smoking status

over and above the cost to achieve an additional

and socioeconomic status, or that were not
present in the database, such as pack-years of

controlled patient. In other words, ICERs in this
case represent the monetary value of the

smoking. We were limited to the available
database information in developing our

intangible benefit to patients or society
beyond the cost to achieve an additional

asthma control measure; however, it would

controlled patient over the outcome period

have been of interest to also include
patient-reported outcomes (including actual

[44].
The ICER of £51,000 for prescribing FDC ICS/

SABA use rather than inhalers prescribed) in

LABA therapy instead of ICS dose step-up was

2002–2004,

direct

medical

costs
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calculated using a composite database measure

fine-particle

ICS

(MMAD

of

2.4–3.2 lm,

of

depending

on

formulation)

had C84%

risk-domain

asthma

control

as

the

effectiveness measure. The more common
calculation
of
ICER
per
additional

probability of being the preferred treatment,
i.e., less costly and more effective, in both the

quality-adjusted life-year (QALY), as used by
the UK National Institute for Health and Care

UK and the USA [49]. Further observational
studies
are
needed
to
compare
the

Excellence (NICE), was not possible from the

cost-effectiveness of step-up regimens with

available data. The cost-effectiveness threshold
used by NICE is £20,000 to £30,000 for cost per

other extrafine-particle ICS, such as ciclesonide
(MMAD of 1.0 lm), and the standard

QALY [45]. Because of our approach in using an
intermediate effectiveness measure instead of a

fine-particle ICS, such as fluticasone (MMAD,
2.4–5.4 lm)
and
budesonide

composite measure such as QALYs, we cannot

(MMAD, *4.0 lm).

make comparisons to results from cost-utility
analyses for unrelated interventions or
treatments. To increase comparability with
unrelated interventions, future pragmatic trials

CONCLUSIONS

to

We found that, among available step-up
therapy alternatives for adults with persistent

calculate both within-trial cost-per-QALY
ratios and projected lifetime cost-per-QALY

asthma on ICS monotherapy cared for in UK
clinical practice, adding a LABA via separate

ratios
using
assumptions
asthma-specific mortality.

inhaler

should

address

treatment

preferences

around

In addition, our study findings apply
primarily to the UK healthcare system, and
further investigations are needed from other
perspectives, using different effectiveness
measures, and in the setting of other
healthcare systems, as costs are highly variable
among countries. Moreover, prescribing
preferences can vary according to location.
Assessment of indirect costs is needed as well.
We chose to investigate extrafine-particle
beclomethasone, with aerosol particle MMAD
of 1.1 lm, for the ICS step-up therapy because of
its good distribution to the small airways, often
a site of persistent inflammation in patients
with poorly controlled asthma [18, 46–48]. In a
prior, similarly designed cost-effectiveness
study of patients initiating ICS therapy for

is

the

least

cost-effective

option.

Increasing extrafine-particle ICS dose is
significantly less costly from the payer
perspective and marginally (non-significantly)
less effective than FDC ICS/LABA therapy
containing standard fine-particle ICS. From the
UK NHS payer perspective, the cost to achieve
an additional controlled patient using an FDC
ICS/LABA combination rather than ICS dose
step-up using extrafine particles is very high
(£51,449). In countries with strong economic
constraints, this may lead to questioning the
recommendation of FDC ICS/LABA as first
choice when treatment step-up is required,
especially
when
considering
that
extrafine-particle ICS dose step-up has a 44%
probability of being the cost-effective option
relative to FDC ICS/LABA. These findings

asthma, we found that initiating with an

warrant further investigation in other
healthcare systems and with a range of ICS in

extrafine ICS as compared with standard

pragmatic trials and observational studies.
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